Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/06—Dipeptides
  • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/69—Boron compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/05—Dipeptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
  • C07F5/02—Boron compounds
  • C07F5/025—Boronic and borinic acid compounds
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
  • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone

Definitions

• the present invention relates to a novel and improved process for preparation of bortezomib mannitol ester.
• Bortezomib is a modified dipeptidyl boronic acid derivative derived from leucine and phenyl alanine.
• the chemical name is [(lR)-3-methyl-l-[[(2S)-l-oxo-3-phenyl-2- [(pyrazinylcarbonyl)amino]propyl]amino]butyl] boronic acid and represented as follows:
• Bortezomib is marketed as Velcade and Bortenat (generic), and is used to treat lymphomas.
• proteasome inhibitors including boronic acid compounds are useful for treating infarcts such as those that occur during stroke or myocardial infarction.
• WO9915183 describes that proteasome inhibitors are useful for treating inflammatory and autoimmune diseases.
• alkylboronic acids are relatively difficult to obtain in analytically pure form. Snyder et al, J: Am. Chew. Soc, 3611 (1958), teaches that alkylboronic acid compounds readily form boroxines (anhydrides) under dehydrating conditions and their boroxines are often air-sensitive. Korcek et al, J. Chem. Soc, Perkin Trans. 2 242 (1972), teaches that butylboronic acid is readily oxidized by air to generate 1-butanol and boric acid. These difficulties were limiting the pharmaceutical utility of boronic acid compounds.
• Bortezomib (a boronic acid compound), in its solid state as a pure API existed in the form of highly water insoluble boroxine, a cyclic boronic acid anhydride. When placed in water, the boroxine ' dissociated to form equilibrium between itself and the monomeric bortezomib resulting in an apparent water solubility of about 0.5-lmg/ml which was not sufficient for formulation purposes.
• the innovator company in their patent WO2002059130 application has described a stable formulation containing mannitol ester of bortezomib.
• the application '9130 also relates to a process of preparing such formulation by first dissolving the bortezomib in warm (temperature around 45 ⁇ 2°C) TBA (tertiary butyl alcohol), then adding water and mannitol (1% bulking agent), followed by freeze drying. On reconstitution, Bortezomib was found to rapidly dissolve and more soluble in water due to the in situ formation of boronic acid esters by reaction with diol groups of mannitol during the alcohol lyophilisation or freeze-drying process.
• TBA tertiary butyl alcohol
• the present invention provides an industrially advantageous process for preparation of bortezomib-mannitol ester which avoids drawbacks associated with the prior art processes.
• the bortezomib-mannitol ester prepared by the process of the invention is substantially free of degradation impurity X.
• the present invention also provides substantially pure bortezomib-mannitol ester.
• the present invention provides a process for the preparation of bortezomib- mannitol ester (compound B)
• reaction that involves a simple chemical reaction, the reaction comprising:
• the present invention provides bortezomib-mannitol ester prepared by a process of the present invention.
• the present invention provides sterile non-lyophilized bortezomib-mannitol ester.
• the present invention provides sterile non-lyophilized bortezomib- mannitol ester prepared by a process of the present invention.
• the present invention provides a pharmaceutical composition comprising bortezomib-mannitol ester.
• the present invention provides a pharmaceutical composition comprising bortezomib-mannitol ester prepared by a process of the present invention.
• the present invention provides a pharmaceutical composition comprising sterile non-lyophilized bortezomib-mannitol ester prepared by a process of the present invention.
• the present invention provides bortezomib-mannitol ester prepared by a process of the present invention for use in treating or preventing relapsed multiple myeloma and mantle cell lymphoma.
• the present invention provides sterile non-lyophilized bortezomib-mannitol for use in treating or preventing relapsed multiple myeloma and mantle cell lymphoma.
• the present invention provides a method of treating or preventing relapsed multiple myeloma and mantle cell lymphoma comprising administering to a patient in need thereof bortezomib-mannitol ester prepared by a process of the present invention.
• the present invention provides a method of treating or preventing relapsed multiple myeloma and mantle cell lymphoma, comprising administering to a patient in need thereof sterile non-lyophilized bortezomib-mannitol ester by a process of the present invention.
• the present invention provides a use of bortezomib-mannitol ester of the invention for the manufacture of a medicament for the treatment or prevention of relapsed multiple myeloma and mantle cell lymphoma in a patient.
• the present invention provides a use of sterile non-lyophilized bortezomib-mannitol ester of the invention for the manufacture of a medicament for the treatment or prevention of relapsed multiple myeloma and mantle cell lymphoma in a patient.
• Substantially pure bortezomib-mannitol ester may be defined as bortezomib-mannitol ester having about 0.3% by weight of impurity X or less, preferably about 0.2 % by weight of impurity X or less, more preferably about 0.1% by weight of impurity X or less.
• the term "residue” is defined to mean the material left behind after the first solvent is removed from the first solution.
• the residue comprises of bortezomib-mannitol ester, although other substances may be present in small amounts, such as mannitol, free bortezomib and the trimetric boroxine form of bortezomib.
• the term "sterilisation” is defined to mean a process that renders the first solution sterile, by removing any life form or any pathological agent from the first solution, such as fungi, bacteria, viruses, or any other microorganism. After such sterilisation, the first solution is rendered free of any agent capable of causing an infection in a patient. Sterilisation by filtration involves the physical removal of such life forms or pathological agents from a solution, which are not occluded since they are not able to pass through the pores of the filter.
• the present invention provides sterile non-lyophilized bortezomib-mannitol ester.
• the sterile non-lyophilized bortezomib-mannitol ester prepared by the process of the invention is substantially free of degradation impurity X.
• the present invention also provides substantially pure sterile non-lyophilized bortezomib-mannitol ester.
• non-lyophilized bortezomib-mannitol ester means bortezomib- mannitol ester which has not been subjected to lyophilisation, or was not lyophilised.
• the process of lyophilisation would comprise freezing a solution of bortezomib-mannitol ester, and subjecting a frozen solution to reduced pressure, thus in one aspect, the term may also mean a bortezomib-mannitol ester prepared by a process where a solution of the bortezomib- mannitol ester was not frozen.
• Substantially pure sterile non-lyophilized bortezomib-mannitol ester may be defined as sterile non-lyophilized bortezomib-mannitol ester having about 0.3% by weight of impurity X or less, preferably about 0.2 % by weight of impurity X or less, more preferably about 0.1 % by weight of impurity X or less.
• the present invention provides a process for preparation of sterile non- lyophilised bortezomib-mannitol ester, wherein the process comprises:
• Bortezomib may form esters with polyols comprising two hydroxyl groups on adjacent carbon atoms.
• the polyol is a sugar alcohol or a reduced sugar.
• the sugar alcohol or reduced sugar is selected from mannitol, sorbitol or xylitol. Either the racemate, D- or L-form of mannitol, sorbitol or xylitol may be used. More preferably, the reduced sugar moiety is mannitol. Whilst racemic of mannitol or L-mannitol may be used, D-mannitol is particularly preferred.
• the structure of bortezomib-mannitol ester, where the mannitol is D-mannitol, is shown below.
• a sugar may be used to form an ester with bortezomib.
• the sugar is selected from fructose, glucose or sucrose.
• An advantage of the process of the present invention is that excessive use of solvents is avoided or minimised.
• Other advantages of the present invention include the use of a convenient, industrially feasible and economical vacuum drying method, which avoids the expensive alcohol lyophilisation process as reported in the prior art. Avoiding lyophilisation can itself contribute to huge cost-reductions when preparing bortezomib-mannitol ester on an industrial scale.
• the present invention is also advantageous in that the esterification process is efficient, in that it avoids the drawbacks associated with reported prior art processes as confirmed by comparative NMR study between bortezomib-mannitol ester compound formed by the process of the present invention and the two commercially available bortezomib products (i.e. Bortenat and VELCADE), based on the evaluation of boronic acid to boronic ester ratio in respective samples.
• the process of the present invention may not involve the use of water, and may be conducted at a much lower temperature, thus resulting in the formation of a pure product substantially free of the degradation impurity X, i.e. N-((S)-1- ((R)-l-hydroxy-3-metl ⁇ lbutylamino)-l-oxo-3 ⁇ henylpropan-2-yl)pyrazim
• the bortezomib mannitol ester formed according to the present invention exhibits an increased solubility of the drug bortezomib in water.
• the substantially pure bortezomib-mannitol ester (including sterile non-lyophilised bortezomib-mannitol ester) are preferably prepared by the processes as described herein.
• a pharmaceutical composition comprising substantially pure bortezomib-mannitol ester (including sterile non-lyophilised bortezomib-mannitol ester), together with one or more pharmaceutically acceptable excipients.
• the pharmaceutical compositions of the invention may be prepared according to methods known in the art.
• the suitable pharmaceutically acceptable excipients for inclusion in such pharmaceutical compositions would be known to those skilled in the art.
• a pharmaceutical composition of the invention in the manufacture of a medicament for the treatment of relapsed multiple myeloma and mantle cell lymphoma.
• a method of treating a subject with relapsed multiple myeloma and mantle cell lymphoma comprising administering a bortezomib-mannitol ester (including sterile non-lyophilised bortezomib- mannitol ester) according to the present invention to a patient in need thereof.
• a bortezomib-mannitol ester including sterile non-lyophilised bortezomib- mannitol ester
• Figures 1 and 2 each show ID 1H-nuclear magnetic resonance (NMR) spectra of two samples of bortezomib-mannitol ester prepared in accordance with the present invention. Details regarding the NMR acquisition parameters are provided in example 7.
• Figure 3 shows the C NMR spectrum of a sample of bortezomib-mannitol ester prepared in accordance with the present invention, between 0 to 110 ppm.
• Figure 4 shows the 13 C NMR spectrum of a sample of bortezomib-mannitol ester commercially available as Bortenat, between 0 to 110 ppm.
• compound B bortezomib-mannitol ester
• the process of the invention results in the formation of compound B substantially free of degradation impurity X.
• substantially free of degradation impurity X refers to bortezomib-mannitol ester having about 0.3% by weight of impurity X or less, preferably about 0.2 % by weight of impurity X or less, more preferably about 0.1% by weight of impurity X or less.
• the impurity X related to bortezomib-mannitol ester as determined by high performance liquid chromatography (HPLC). According to an aspect of the present invention, there is provided a process for the preparation of compound B that comprises;
• Compound A used as a starting material may be prepared by the processes known in the prior art, for example as per the process described in the IN patent application No. 2638/MUM/2012, and in WO 14/041324, which are both incorporated herein by reference in their entirety.
• the process for preparation of compound B may comprise reacting compound A with a reduced sugar moiety, like mannitol, wherein mannitol is preferably of D-configuration.
• the process may comprise of adding compound A in a first solvent selected from methanol, isopropyl alcohol, ethanol, methylene dichloride, ethyl acetate and tetrahydrofuran, or any mixture thereof, that can be used in place of TBA (tertiary butyl alcohol) used by the prior art, to obtain a chemically stable compound B.
• a first solvent selected from methanol, isopropyl alcohol, ethanol, methylene dichloride, ethyl acetate and tetrahydrofuran, or any mixture thereof, that can be used in place of TBA (tertiary butyl alcohol) used by the prior art, to obtain a chemically stable compound B.
• TBA tertiary butyl alcohol
• a large amount of TBA is required to dissolve bortezomib, which is undesirable from both a cost perspective and disposal concerns.
• Use of TBA also involves a higher temperature in order to dissolve the bortezomib,
• the process for preparing compound B comprises treating compound A with mannitol in a first solvent, without involving water, at a preferably lower temperature of 27 ⁇ 2°C, that thereby obtain the formation of compound B substantially free of the degradation impurity X.
• the temperature for reaction is preferably 27 ⁇ 2°C, but it will be appreciated that other temperatures may be used, including less than 30 °C, less than 31 °C, less than 32 °C, less than 33 °C, less than 34 °C, less than 35 °C, less than 36 °C or less than 37 °C.
• the temperature is preferably higher than 10 °C
• the reaction time is preferably 15 minutes, but it will be appreciated that longer reaction times may be used, including less than 17 minutes, less than 19 minutes, less than 19 minutes, less than 20 minutes, less than 21 minutes, less than 23 minutes, less than 25 minutes, less than 27 minutes, less than 29 minutes, or less than 30 minutes.
• the reaction time is preferably longer than 5 minutes.
• a solid form of compound B is produced when compound A is treated with mannitol in a first solvent.
• the first solvent is preferably polar. Suitable polar solvents include methanol, isopropyl alcohol, ethanol, methylene dichloride, ethyl acetate, tetrahydrofuran, and mixtures thereof.
• the first solvent is preferably substantially free of water.
• substantially free of water means less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, less than 0.1%, less than 0.05%, or 0% [all percentages in (v/v)]. It will be appreciated that very small amounts of water may be present in the first solvent; however, such small amounts should be avoided where possible, and where a small amount is present, it is incidental, and its presence unintentional.
• the process further comprises adding a second solvent to the residue to form a suspension of bortezomib-mannitol ester in the second solvent, and isolating the bortezomib-mannitol ester from the second solvent.
• the second solvent is preferably water immiscible. More preferably, the second solvent used is selected from the group consisting of: n-heptane, hexane, toluene, cyclohexane, diisopropyl ether, diethyl ether, and any combination thereof.
• the second solvent is preferably substantially free of water.
• the process further comprises removing the first solvent from the first solution to form a residue comprising bortezomib-mannitol ester.
• Removal of the first solvent is preferably carried out by evaporating the first solvent from the first solution, for instance by heating or distilling the first solvent, and/or subjecting the first solution to a reduced pressure (such as a pressure less than 1 atmosphere).
• the reduced pressure is pressure is less than 1 atmosphere.
• the pressure may be less than 0.8 atmospheres, 0.6 atmospheres, 0.4 atmospheres, 0.3 atmospheres, 0.2 atmospheres, 0.1 atmospheres, 0.05 atmospheres, or 0.02 atmospheres.
• the pressure is preferably higher than 0.01 atmospheres.
• the temperature at which the first solvent is evaporated is preferably lower than ambient temperature, i.e. 30°. More preferably the temperature is less than 28°C, 26°C, 25°C, 24°C, 23°C, or 22°C. A temperature higher than 10°C is preferred.
• isolation of compound B may be carried out by filtering the solid. The filtrate may be washed with an amount of the second solvent.
• the solid is preferably dried under vacuum at 43 ⁇ 2°C, but other temperatures may be used, including than 47 °C, less than 49 °C, less than 51 °C, less than 53 °C, less than 55 °C or less than 57 °C.
• the temperature is preferably higher than 20 °C.
• Compound B (bortezomib-mannitol ester) obtained in accordance with the present invention advantageously shows better water solubility i.e. soluble in around 5 volumes water, than the poorly water soluble drug bortezomib.
• a further advantage of the present invention is to provide compound B with low levels of free boronic acid.
• the present invention provides a product where the ratio of bortezomib-mannitol ester to bortezomib is greater than 1 :0.09, preferably greater than 1 :0.08, and most preferably greater than 1 :0.07.
• the process of the invention results in the formation of compound C substantially free of degradation impurity X.
• the term "substantially free” refers to bortezomib- mannitol ester having about 0.3% by weight of impurity X or less, preferably about 0.2 % by weight of impurity X or less, more preferably about 0.1% by weight of impurity X or less.
• the impurity X related to bortezomib mannitol ester may be determined by high performance liquid chromatography (HPLC).
• the present invention provides sterile non-lyophilised bortezomib-mannitol ester.
• a process for the preparation of sterile non-lyophilised bortezomib-mannitol ester that comprises;
• the first solution may be sterilised by filtration. This can be achieved by passing the first solution through a sub-micron filter, such as a 0.22 micron filter.
• the first solution may optionally be passed through a 0.45 micron filter, which may assist in removing larger insoluble matter from the first solution, and thus decreasing the chance of blocking the 0.22 micron filter. Filters with even smaller pore sizes may be used, such as those with 50 nm, or 20 nm, if desired.
• the present invention also relates to an advantageous process of preparing bortezomib- mannitol ester as depicted in scheme 1, which being a chemically induced process may increase the scope of introducing variables or specific functional groups at certain structural positions of the drug ester, which can further open a new route of investigation of structural modifications of bortezomib-mannitol esters by subsequently monitoring their activities.
• a pharmaceutical composition comprising the bortezomib-mannitol ester of the present invention, with one or more pharmaceutically acceptable excipients.
• a process of preparing the pharmaceutical composition comprising bortezomib-mannitol ester of the present invention along with pharmaceutically acceptable excipients.
• Compound B formed in accordance with the invention was analysed using NMR.
• ID 1H-nuclear magnetic resonance (NMR) analysis was performed by dissolving compound B in approximately 0.7 mL solution of 0.9% NaCl (w/v) in 10% D 2 O/90% H 2 0 (v/v) on a Varian 500 MHz NMR spectrometer using following parameters to determine a boronic acid to boronic ester ratio.
• the 1H NMR spectrum recorded in duplicate revealed a boronic acid (i.e. bortezomib) to boronic ester (i.e. bortezomib-mannitol ester) ratio of approximately 0.06:1 and 0.07:1, as depicted in the Figure 1 and Figure 2, respectively.
• the region from 2.35 to 2.85 ppm represents the integrated signal from the protons of free bortezomib and ester wherein the peak at -2.73 ppm is assigned to the free bortezomib and the peak at ⁇ 2.62 ppm is assigned to the bortezomib-mannitol ester.
• free bortezomib to bortezomib-mannitol ester ratio reported in the art for Bortenat and VELCADE samples and the one for compound B.
• the 13 C NMR spectrum of compound B therefore matches with 13 C NMR spectrum of lyophilized material of Bortenat Injection sample.
• the NMR data shows that that boronic acid: boronic ester ratio of compound B (bortezomib-mannitol ester) is on lower side (0.07:1) as compared to the values of both commercially available VELCADE and Bortenat samples, thus confirming that the processes of the present invention provide bortezomib-mannitol ester which is superior over the prior art.
• Example 8 Preparation of bortezomib mannitol ester for injection (3.5mg bortezomib / 3.5 ml vial)

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (2)

Family

ID=50549349

Family Applications (1)

Country Status (6)

Cited By (5)

Citations (18)

Family Cites Families (3)

• 2014
  • 2014-04-16 EP EP14719344.5A patent/EP2986619A1/en not_active Withdrawn
  • 2014-04-16 CA CA2909519A patent/CA2909519A1/en not_active Abandoned
  • 2014-04-16 WO PCT/GB2014/000150 patent/WO2014170628A1/en not_active Ceased
  • 2014-04-16 IN IN1431MU2013 patent/IN2013MU01431A/en unknown
  • 2014-04-16 ZA ZA2014/02789A patent/ZA201402789B/en unknown
  • 2014-04-16 US US14/784,866 patent/US10023611B2/en not_active Expired - Fee Related

Patent Citations (22)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events